G
62.75
8.35 (15.35%)
| Previous Close | 54.40 |
| Open | 56.00 |
| Volume | 1,257,354 |
| Avg. Volume (3M) | 1,254,760 |
| Market Cap | 2,693,016,064 |
| Price / Sales | 13.50 |
| Price / Book | 0.900 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Operating Margin (TTM) | -482.59% |
| Diluted EPS (TTM) | -59.59 |
| Quarterly Revenue Growth (YOY) | 19.10% |
| Total Debt/Equity (MRQ) | 2.67% |
| Current Ratio (MRQ) | 9.70 |
| Operating Cash Flow (TTM) | -464.88 M |
| Levered Free Cash Flow (TTM) | -236.88 M |
| Return on Assets (TTM) | -11.98% |
| Return on Equity (TTM) | -62.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | GRAIL, Inc. | Bearish | Bullish |
AIStockmoo Score
2.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| % Held by Insiders | 14.18% |
| % Held by Institutions | 66.50% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crcm Lp | 31 Dec 2025 | 1,072,374 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 82.00 (Baird, 30.68%) | Buy |
| Median | 80.00 (27.49%) | |
| Low | 60.00 (Morgan Stanley, -4.38%) | Hold |
| Average | 74.00 (17.93%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 50.26 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 24 Feb 2026 | 60.00 (-4.38%) | Hold | 50.35 |
| Baird | 20 Feb 2026 | 82.00 (30.68%) | Buy | 50.21 |
| 17 Feb 2026 | 113.00 (80.08%) | Buy | 99.03 | |
| Canaccord Genuity | 20 Feb 2026 | 80.00 (27.49%) | Buy | 50.21 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |